These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9. Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281 [TBL] [Abstract][Full Text] [Related]
24. Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation. Rymer JA; Mues KE; Monda KL; Bratton EW; Wirtz HS; Okerson T; Overman RA; Brookhart MA; Muntner P; Wang TY J Am Heart Assoc; 2020 May; 9(9):e014347. PubMed ID: 32326795 [TBL] [Abstract][Full Text] [Related]
25. Predictors of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitor Prescriptions for Secondary Prevention of Clinical Atherosclerotic Cardiovascular Disease. Blumenthal DM; Maddox TM; Aragam K; Sacks CA; Virani SS; Wasfy JH Circ Cardiovasc Qual Outcomes; 2021 Sep; 14(9):e007237. PubMed ID: 34404223 [TBL] [Abstract][Full Text] [Related]
26. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Joseph L; Robinson JG Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907 [TBL] [Abstract][Full Text] [Related]
27. Patient adherence to fully reimbursed proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) treatment. Stummer A; Ristl R; Kogler B; Muskovich M; Kossmeier M; Stulnig TM Wien Klin Wochenschr; 2023 Jul; 135(13-14):375-382. PubMed ID: 36808306 [TBL] [Abstract][Full Text] [Related]
34. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia. Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088 [TBL] [Abstract][Full Text] [Related]
35. The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function. Di Costanzo A; Indolfi C; Sorrentino S; Esposito G; Spaccarotella CAM Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511498 [TBL] [Abstract][Full Text] [Related]
36. Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition. Ouyang M; Li C; Hu D; Peng D; Yu B Clin Chim Acta; 2023 Jan; 538():113-123. PubMed ID: 36403664 [TBL] [Abstract][Full Text] [Related]
37. Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom. Tai MH; Shepherd J; Bailey H; Williams N; Hatz M; Campos Tapias I; Catterick D; Worth G Curr Med Res Opin; 2019 May; 35(5):829-835. PubMed ID: 30289004 [TBL] [Abstract][Full Text] [Related]
38. Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies. Oleaga C; Shapiro MD; Hay J; Mueller PA; Miles J; Huang C; Friz E; Tavori H; Toth PP; Wójcik C; Warden BA; Purnell JQ; Duell PB; Pamir N; Fazio S J Am Coll Cardiol; 2021 Oct; 78(14):1437-1449. PubMed ID: 34593126 [TBL] [Abstract][Full Text] [Related]
39. Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis. Lu X Curr Drug Targets; 2019; 20(10):1029-1040. PubMed ID: 30767742 [TBL] [Abstract][Full Text] [Related]
40. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia. Ferri N; Ruscica M Endocrine; 2016 Dec; 54(3):588-601. PubMed ID: 27038318 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]